A team of researchers has won funding from the US Air Force Office of Scientific Research to address the challenges posed by silicon spin qubits.
Recent technological advances have enabled the development of increasingly sophisticated sensors, which can help to advance the sensing capabilities of robots, drones, autonomous vehicles, and other smart systems. Many of these sensors, however, rely on individual cameras, thus the accuracy of the measurements they collect is limited by the cameras’ field of view (FOV).
Researchers at Beihang University in China recently developed a new multi-camera differential binocular vision sensor with a wider FOV that could collect more accurate measurements. This sensor, introduced in a paper published in Optics & Laser Technology, could be integrated into a wide range of devices and smart robotic systems.
“Aiming at the high-precision requirements of environment perception for unmanned aerial vehicle detection, robot navigation, and autonomous driving, inspired by the multi-camera module of mobile phones, we introduced a visual perception mode based on the principle of high-precision binocular vision measurement,” Fuqiang Zhou, co-author of the paper, told Tech Xplore. “This principle involves a central high-resolution camera and peripheral auxiliary cameras that work together.”
In an interview with WIRED, DeepMind CEO Demis Hassabis says the biggest breakthroughs in AI are yet to come—and will take more than just chips.
The notoriously pessimistic AI researcher Eliezer Yudkowsky is back with a new prediction about the future of humankind.
“If you put me to a wall,” he told The Guardian in a fascinating new interview, “and forced me to put probabilities on things, I have a sense that our current remaining timeline looks more like five years than 50 years. Could be two years, could be 10.”
If you’re wondering what “remaining timeline” means in this context, The Guardian’s Tom Lamont interpreted it as the “machine-wrought end of all things,” a “Terminator-like apocalypse,” or a “Matrix hellscape.”
Macquarie University neuroscientists have developed a single-dose genetic medicine that has been proven to halt the progression of both motor neuron disease (MND) and frontotemporal dementia (FTD) in mice—and may even offer the potential to reverse some of the effects of the fatal diseases.
It may also hold opportunities for treating more common forms of dementia, such as Alzheimer’s disease, which is the second most common cause of death in Australia after heart disease.
The new treatment, dubbed CTx1000, targets pathological build-ups of the protein TDP-43 in cells in the brain and spinal cord.
Neurologic immune-related adverse events (nirAEs) following immune checkpoint inhibitor therapy for cancer are frequent and varied; a recent study identified risk factors for death after nirAEs.
Recent cohort studies have demonstrated that neurologic immune-related adverse events (nirAEs) following immune checkpoint inhibitor (ICI) therapy for cancer are frequent, varied, and associated with higher overall survival (NEJM JW Neurol Sep 29 2023 and Neurology 2023; 101:e2472). Researchers conducted a retrospective cohort study of consecutive patients referred to a tertiary center during a 5-year period to characterize the clinical features of nirAEs and identify predictors of ICI response and survival.
The researchers identified 64 patients with confirmed nirAEs, 81% involving the central nervous system (CNS). The vast majority of CNS nirAE patients had encephalopathy, of which 73% were neither seropositive for well-characterized neural autoantibodies, nor had a distinctive encephalitis syndrome, nor had evidence of CNS inflammatory changes. The most common peripheral nervous system (PNS) syndrome was myasthenia and myositis (with or without myocarditis) overlap syndrome. Only 17% of PNS nirAE patients were seropositive. Steroids were given to 91% of nirAE patients after a median of 90 days of symptoms, and 48% received additional immunotherapy. At 1-month follow-up, 72% of nirAE patients showed improvement, 9% had worsened, and 17% had died. Among the 53 patients who survived the first month, median follow-up was 6 months; during follow-up, 30% died, most commonly of cancer progression or cancer-related complications. Death was associated with lung cancer (hazard ratio, 2.
Talk by Ken Dickerson, CRISPR Group Leader, CRISPR QC, at the BACE Technology Showcase event in August 2022.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, potentially fatal condition caused when bloodclots in the lungs block blood vessels to the heart. Yale PCCSM’s Phillip Joseph, MD, and Yale Cardiac Surgery’s Prashanth Vallabhajosyula, MD, share how Yale’s highly specialized #
Clinicians diagnose and treat CTEPH.
The UK’s high-powered DragonFire laser weapon just shot down its first drones — bringing it one step closer to the battlefield.